Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
Biogen's swing and miss in Alzheimer's disease has weighed on its shares this year.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Alert: Top Cash Back Card Now Offers 0% Intro APR Until Nearly 2027
Enjoy 0% intro APR on purchases and balance transfers for 15 months—plus up to 5% cash back in popular categories.
Motley Fool Returns
Market-beating stocks from our flagship service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 2025-08-28 23:30:29.485449.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Biogen (BIIB 0.03%), a blue chip biotech stock, has shed an unsightly 22.3% of its value over the course of the first six months of 2019, according to data from S&P Global Market Intelligence. The biotech's shares have taken a bath this year for three reasons:
Image source: Getty Images.
Biogen's sharp dip has fueled speculation that the biotech might pursue one or more tuck-in acquisitions soon. So far, though, it's only acquired the early-stage gene therapy company Nightstar Therapeutics in 2019, which isn't expected to change its outlook anytime soon.
The good news is that Biogen does have ample financial capacity for business development activities, but management has also shown little appetite for costly acquisitions during their tenure. So, it's unclear whether Biogen will ultimately make a needle-mover transaction.
Biogen's steep drop during the first half of 2019, though, may have created a compelling entry point for bargain hunters. At less than eight times next year's projected earnings, after all, Biogen is one of the cheapest large-cap biotech stocks in the market right now.
The flip side of this argument is that the company's future is rather murky in the wake of this Alzheimer's disease setback. Biogen doesn't have a particularly robust late-stage pipeline to fall back on and its management team appears content to rely on earlier-stage assets to create shareholder value. Thus, this top biotech stock may continue to struggle for the foreseeable future.